biotech · Presbyopia · Eye Diseases · LENZ
LENZ Therapeutics
LENZ Therapeutics is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker LENZ. Primary therapeutic focus areas include Presbyopia, Eye Diseases. NovaPharmaNews links 5 clinical program(
San Diego, USA HQ
176 Employees
Public company Type
LENZ · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Employees
- 176
- Programs
- 5
- Drugs
- 6
- Patents
- 20
Aceclidine+Brimonidine combination ophthalmic solution
Phase 3 · small molecule · Presbyopia
Aceclidine+Brimonidine combination ophthalmic solution for Presbyopia is a Phase 3 program (small_molecule) at LENZ Therapeutics with 6 ClinicalTrials.gov record(s).
Internal code 22-150-0018
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- LENZ Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Presbyopia
- Status
- completed
- Trials
- 6